KCRSBeyond's analysis on KCRS2026-07-27 — Kura Oncology’s positive combo data could accelerate a new treatment option for advanced clear cell renal cell carcinomaRecent news mentioning KCRS2026-07-27 — Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026Browse the full archive →